Volume 18, Number 8—August 2012
CME ACTIVITY - Research
Factors Related to Increasing Prevalence of Resistance to Ciprofloxacin and Other Antimicrobial Drugs in Neisseria gonorrhoeae, United States
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at www.medscape.org/journal/eid; (4) view/print certificate.
Release date: July 16, 2012; Expiration date: July 16, 2013
Upon completion of this activity, participants will be able to:
• Describe overall patterns of drug resistance stratified by sexual orientation, based on an analysis of data from GISP
• Describe the association of recent travel with drug resistance in MSM and heterosexuals, based on an analysis of data from GISP
• Describe the first appearance of drug resistance in heterosexuals and MSM, based on an analysis of data from GISP.
Carol E. Snarey, MA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Carol E. Snarey, MA, has disclosed no relevant financial relationships.
Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.
Disclosures: Edward Goldstein, PhD; Robert D. Kirkcaldy, MD, MPH; David Reshef; Stuart Berman, MD; Hillard Weinstock, MD, MPH; Pardis Sabeti, MD, DPhil; Geraldine Hall, PhD; and Marc Lipsitch, PhD, have disclosed no relevant financial relationships. Carlos Del Rio, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Gilead Sciences; received grants for clinical research from Merck and Co. Edward W. Hook, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Cempra; served as a speaker or a member of a speakers bureau for Becton Dickinson; received grants for clinical research from Becton Dickinson, Cepheid, Roche Molecular, Gen-Probe Inc., Cempra, Siemens, GlaxoSmithKline; acted as a book editor and received royalties from McGraw Hill.
- Page created: July 17, 2012
- Page last updated: July 17, 2012
- Page last reviewed: July 17, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)